Keiji AI LogoKeiji AI

Clinical Operations guide

AI for clinical trial site selection: how it works and how to compare tools

How AI ranks clinical trial sites on enrollment and diversity, what data each kind of tool uses, the published evidence, and a checklist for choosing one.

AI site selection ranks candidate sites by how many eligible patients each is likely to enroll, and can weigh patient diversity alongside speed. Tools differ mainly in their data: cross-industry trial history (Medidata), a CRO's own site network (IQVIA), a curated investigator database (Citeline Sitetrove+), a federated EHR network (TriNetX), or the sponsor's own data, which is where TrialMind runs. Peer-reviewed studies show machine-learning rankings beating common industry baselines, and FRAMM showed diversity can rise without giving up enrollment. Pick by the data you need and ask every vendor for the trade-off and reasoning behind each ranked site.

What AI site selection does

Site selection decides most of a trial's enrollment speed. Most sponsors still start from a list of familiar sites and their past enrollment. AI adds two things: it scores many more candidate sites against the actual protocol, and it predicts each site's patient mix as well as its volume.

A typical AI run works in four steps:

  1. Read the protocol. Indication, phase, eligibility criteria and the enrollment target, from the protocol or a ClinicalTrials.gov (NCT) record.
  2. Build the candidate pool. Every site with relevant history or patients, not only the usual list.
  3. Score each site. Expected enrollment from past performance and the eligible patients nearby, plus expected diversity.
  4. Shortlist under constraints. A cap on site count, country mix or budget, with the reason for each pick written out.

The output is a ranked list a feasibility lead can argue with, not a final decision. Site relationships, start-up timelines and investigator interest still come from people.

Five kinds of tools, by the data they use

Vendors describe their products in similar words, so compare them by the data underneath. Each kind answers a different question.

Kind of toolExampleData it usesBest for
Trial platform with cross-industry dataMedidataOperational data from 38,000+ trials and 12M patientsRanking sites and forecasting enrollment from past trial performance
CRO networkIQVIAReal-world, clinical and consumer data, plus its own network sitesOutsourcing site selection and recruitment
Site and investigator databaseCiteline Sitetrove+A curated database of 580K+ investigators and 208K+ sitesFinding and comparing investigators
Federated EHR networkTriNetX LIVEEHR data from 14,200+ sites, which stays at each source (TriNetX)Finding sites with eligible patients and testing criteria
Analysis on your own dataTrialMindYour site history, registered trials and patient data you hold or license, in your environmentRanking sites with your own data and a recorded diversity trade-off

Facts about other vendors come from their own pages, linked above and checked on 29 October 2026. The side-by-side comparison shows each one on patient matching, monitoring and where patient data stays.

These kinds combine. A sponsor can rank sites on its own history, check eligible-patient counts on a federated network, and hand activation to a CRO.

What the published evidence shows

Two peer-reviewed studies are the most useful reference points.

  • Real-world data improves rankings. Hulstaert et al. combined indication-level recruitment history with real-world patient data. Their models ranked sites better than common industry baselines in inflammatory bowel disease and multiple myeloma (PLOS ONE, 2024).
  • Diversity does not have to cost enrollment. FRAMM, from Keiji AI's founders and colleagues, ranks sites on enrollment and diversity together and handles sites with missing data. Evaluated on 4,392 trials matched to 33,323 sites, it reached higher diversity at the same enrollment level than the methods it was compared with (Theodorou et al., Patterns, 2024). The authors present it as a proof of concept.

Vendor-reported results, such as enrollment gains from a single program, are useful but not comparable across vendors. Ask how each number was measured and against what baseline.

Diversity action plans make the trade-off a requirement

FDA's draft guidance on diversity action plans (June 2024) describes enrollment goals by race, ethnicity, sex and age group, with a rationale for each. Site choice is one of the biggest levers for meeting those goals.

That changes what a site-selection tool must record. A ranked list is not enough. The sponsor needs to show how much weight diversity got, which sites it added, and what that cost in expected enrollment time. Ask for the trade-off setting to be saved with every result, so it can go into the plan.

How TrialMind selects sites

TrialMind is Keiji AI's platform of AI agents for clinical research. Its site selection workflow takes a protocol or NCT identifier and returns a ranked list that balances expected enrollment and patient diversity, with the trade-off recorded and the reasoning shown for each site. Ranked lists export as CSV files.

In one example on NCT03100149, a Phase 2 Parkinson's disease study, a fairness-aware run ranked 26,287 candidate sites against a 1,000-patient target and shortlisted five under a five-site cap.

  • Data in: the protocol, historical site and investigator performance, therapeutic-area experience and each site's patient catchment.
  • Deployment: inside your environment. Raw patient records are not moved.
  • Not included: TrialMind has no network of sites or patients and does not run site activation. Teams that want that work done for them should look at a CRO.

The same workflow connects to patient matching and eligibility criteria, so a criterion change can be checked against both the patient pool and the site list.

Checklist for choosing a site-selection tool

  1. Which data, and whose? Trial history, a CRO network, an investigator database, a federated EHR network, or your own data.
  2. Protocol-specific scoring. Does it score sites against your eligibility criteria, or only by indication?
  3. Diversity. Can you set the weight on diversity, and is the setting saved with the result?
  4. Reasoning per site. Every ranked site should come with the evidence behind its score.
  5. Missing history. How are new sites, or sites with little history, handled?
  6. Constraints. Site caps, countries and budgets should be inputs, not a manual step after ranking.
  7. Back-testing. Ask for a run on a trial you have already enrolled and compare the list with what happened.
  8. Data location. Does any patient-level data leave your environment?

Frequently asked questions

What are the best AI tools for clinical trial site selection?
It depends on the data you need. Medidata ranks sites from cross-industry trial data, IQVIA pairs its CRO network with data, Citeline Sitetrove+ is a curated investigator database, TriNetX finds sites with eligible patients on a federated EHR network, and TrialMind ranks sites on your own data in your environment, weighing enrollment and diversity.
How does AI improve site selection?
It scores many more candidate sites against the actual protocol, combining past enrollment with the eligible patients near each site. A PLOS ONE 2024 study found machine-learning rankings outperformed common industry baselines.
Can AI site selection improve trial diversity?
Yes, if diversity is an explicit objective. FRAMM (Patterns, 2024) reached higher diversity at the same enrollment level than the methods it was compared with. Record the diversity weight with each result for the diversity action plan.
Does TrialMind supply sites or patients?
No. TrialMind has no site or patient network. It ranks sites using data you hold or license, inside your environment.

See TrialMind on your own question

A 30-minute walkthrough on a study like yours, with sources and code you can check.